DexaJectThis page contains information on DexaJect for veterinary use.
The information provided typically includes the following:
- DexaJect Indications
- Warnings and cautions for DexaJect
- Direction and dosage information for DexaJect
DexaJectThis treatment applies to the following species:
2 mg per mL
ANADA #200-312, Approved by FDA
FOR ANIMAL USE ONLY
KEEP OUT OF REACH OF CHILDREN
Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Dexamethasone Solution is a synthetic analogue of prednisolone, having similar but more potent anti-inflammatory therapeutic action and diversified hormonal and metabolic effects. Modification of the basic corticoid structure as achieved in DEXAJECT™ offers enhanced anti-inflammatory effect compared to older corticosteroids. The dosage of DEXAJECT™ required is markedly lower than that of prednisone and prednisolone.
DEXAJECT™ is not species-specific; however, the veterinarian should read the sections on INDICATIONS, DOSAGE, SIDE EFFECTS, CONTRAINDICATIONS, PRECAUTIONS, and WARNINGS before this drug is used.
DEXAJECT™ is intended for intravenous or intramuscular administration. Each mL contains 2 mg dexamethasone, 500 mg polyethylene glycol 400, 9 mg benzyl alcohol, 1.8 mg methylparaben and 0.2 mg propylparaben as preservatives, 4.75% alcohol, HCl to adjust pH to approximately 4.9, water for injection q.s.
EXPERIMENTAL STUDIES: Experimental animal studies on dexamethasone have revealed it possesses greater anti-inflammatory activity than many steroids. Veterinary clinical evidence indicates dexamethasone has approximately 20 times the anti-inflammatory activity of prednisolone and 70 to 80 times that of hydrocortisone. Thymus involution studies show dexamethasone possesses 25 times the activity of prednisolone. In reference to mineralocorticoid activity, dexamethasone does not cause significant sodium or water retention. Metabolic balance studies show that animals on controlled and limited protein intake will exhibit nitrogen losses on exceedingly high dosages.
DEXAJECT™ is indicated for the treatment of primary bovine ketosis and as an anti-inflammatory agent in the bovine and equine.
As supportive therapy, DEXAJECT™ may be used in the management of various rheumatic, allergic, dermatologic, and other diseases known to be responsive to anti-inflammatory corticosteroids. DEXAJECT™ may be used intravenously as supportive therapy when an immediate hormonal response is required.
DEXAJECT™ is offered for the treatment of primary ketosis. The gluconeogenic effects of DEXAJECT™, when administered intramuscularly, are generally noted within the first 6 to 12 hours. When DEXAJECT™ is used intravenously, the effects may be noted sooner. Blood sugar levels rise to normal levels rapidly and generally rise to above normal levels within 12 to 24 hours. Acetone bodies are reduced to normal concentrations usually within 24 hours. The physical attitude of animals treated with DEXAJECT™ brightens and appetite improves, usually within 12 hours. Milk production, which is suppressed as a compensatory reaction in this condition, begins to increase. In some instances, it may even surpass previous peaks. The recovery process usually takes from 3 to 7 days.
DEXAJECT™ may be used as supportive therapy in mastitis, metritis, traumatic gastritis, and pyelonephritis, while appropriate primary therapy is administered. In these cases, the corticosteroid combats accompanying stress and enhances the feeling of general well-being. DEXAJECT™ may also be used as supportive therapy in inflammatory conditions, such as arthritic conditions, snake bite, acute mastitis, shipping fever, pneumonia, laminitis, and retained placenta.
DEXAJECT™ is indicated for the treatment of acute musculoskeletal inflammations such as bursitis, carpitis, osselets, tendonitis, myositis, and sprains. If boney changes exist in any of these conditions, joints, or accessory structures, a response to DEXAJECT™ cannot be expected. In addition, DEXAJECT™ may be used as supportive therapy in fatigue, heat exhaustion, influenza, laminitis, and retained placenta provided that the primary cause is determined and corrected.
ADMINISTRATION AND DOSAGE: Therapy with DEXAJECT™, as with any other potent corticosteroid, should be individualized according to the severity of the condition being treated, anticipated duration of steroid therapy, and animal’s threshold or tolerance for steroid excess.
Treatment may be changed over to DEXAJECT™ from any other glucocorticoid with proper reduction or adjustment of dosage.
Bovine: DEXAJECT™:- 5 - 20 mg intravenously or intramuscularly.
Equine: DEXAJECT™: 2.5 - 5 mg intravenously or intramuscularly.
Except for emergency therapy, do not use in animals with chronic nephritis and hyper-corticalism (Cushing’s syndrome). Existence of congestive heart failure, diabetes, and osteoporosis are relative contraindications. Do not use in viral infections during the viremic stage.
PrecautionsAnimals receiving DEXAJECT™ should be under close observation. Because of the anti-inflammatory action of corticosteroids, signs of infection may be masked and it may be necessary to stop treatment until a further diagnosis is made. Overdosage of some glucocorticoids may result in sodium retention, fluid retention, potassium loss, and weight gain.
DEXAJECT™ may be administered to animals with acute or chronic bacterial infections providing the infections are controlled with appropriate antibiotic or chemotherapeutic agents.
Doses greater than those recommended in horses may produce transient drowsiness or lethargy in some horses. The lethargy usually abates in 24 hours.
Use of corticosteroids, depending on the dose, duration, and specified steroid, may result in inhibition of endogenous steroid production following drug withdrawal. In patients presently receiving or recently withdrawn from systemic corticosteroid treatments, therapy with a rapidly acting corticosteroid should be considered in unusually stressful situations.
WarningsClinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis.
Additionally, corticosteroids administered to dogs, rabbits, and rodents during pregnancy have produced cleft palate. Other congenital anomalies including deformed forelegs, phocomelia, and anasarca have been reported in offspring of dogs which received corticosteroids during pregnancy.
A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves to be processed for veal.
Side EffectsSide effects, such as SAP and SGPT enzyme elevations, weight loss, anorexia, polydipsia, and polyuria, have occurred following the use of synthetic corticosteroids in dogs. Vomiting and diarrhea (occasionally bloody) have been observed in cats and dogs. Cushing’s syndrome in dogs has been reported in association with prolonged or repeated steroid therapy.
Corticosteroids reportedly cause laminitis in horses.
How SuppliedDEXAJECT™, 2 mg per mL, 100 mL multiple dose vial.
StorageStore between 2° and 30°C (36° and 86°F).
Manufactured by: Bimeda-MTC Animal Health Inc., Cambridge, ON Canada
Distributed Exclusively by Henry Schein Animal Health, Dublin, OH 43017
NAC No.: 10822554
400 METRO PLACE NORTH, DUBLIN, OH, 43017-7545
|Every effort has been made to ensure the accuracy of the DexaJect information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the US product label or package insert.|
Copyright © 2017 North American Compendiums. Updated: 2017-05-31